Nucor earnings beat by $0.08, revenue fell short of estimates
GSK plc (LSE/NYSE: GSK), a prominent global pharmaceutical company with a market capitalization of $74 billion and currently trading below its InvestingPro Fair Value, announced today the upcoming appointment of Dr. Gavin Screaton to its Board as a Non-Executive Director, effective May 1, 2025. Dr. Screaton, currently Head of the Medical (TASE:BLWV) Sciences Division at the University of Oxford, will replace Dr. Jesse Goodman, who retires following nine years of service.
Dr. Screaton brings to GSK extensive expertise in immunology and infectious diseases, aligning with GSK’s scientific focus as a leading pharmaceutical company generating annual revenues of $39.3 billion. He holds positions as a Fellow of the Academy of Medical Sciences, the Royal College of Physicians, and is involved in public health as a Non-Executive Director at Oxford University Hospitals NHS Foundation Trust and as a Trustee of the Jenner Vaccine Foundation. Additionally, Dr. Screaton co-founded RQ Bio, a biotech company dedicated to developing medicines for viral infectious diseases.
Upon joining, Dr. Screaton will participate in the GSK Board Science Committee and the Corporate Responsibility Committee. Sir Jonathan Symonds, Chair of GSK, expressed confidence that Dr. Screaton’s background will add valuable perspective to the Board, appreciating his scientific acumen in areas crucial to GSK.
The company also acknowledged the significant contributions of Dr. Jesse Goodman, who has been instrumental in providing expertise in infectious diseases, regulation, and public health during his tenure.
Dr. Screaton’s appointment followed a comprehensive search process, led by an external firm, and was recommended by the Nominations & Corporate Governance Committee. The Board has confirmed Dr. Screaton as an independent Non-Executive Director in accordance with the UK Corporate Governance Code.
He will receive the standard Non-Executive Director fee and an additional fee for his scientific and medical expertise. Dr. Screaton will also be expected to meet the share ownership requirements as per the company’s policy.
GSK, a global biopharma company with a strong financial health rating according to InvestingPro, focuses on uniting science, technology, and talent to combat disease. The company maintains a robust 71.8% gross profit margin and has consistently paid dividends for 25 consecutive years. The company’s leadership team will continue to drive its mission forward with this new appointment. For comprehensive analysis and additional insights, including 8 more ProTips and detailed financial metrics, explore GSK’s Pro Research Report, available exclusively on InvestingPro.
This report is based on a press release statement and does not contain any forward-looking statements.
In other recent news, GlaxoSmithKline (NYSE:GSK) reported fourth-quarter revenue of £8.12 billion, exceeding analyst expectations, although adjusted earnings per share fell short at £0.23 compared to the anticipated £0.49. The company’s revenue growth was primarily driven by its Specialty Medicines segment, which saw a 17% increase in sales, with notable contributions from HIV and Oncology drugs. However, the Vaccines segment experienced a 12% decline in sales, largely due to reduced demand for the RSV vaccine Arexvy. GSK has announced a £2 billion share buyback program over the next 18 months and anticipates revenue growth of 3-5% and adjusted EPS growth of 6-8% for 2025.
Additionally, GSK’s new 5-in-1 meningitis vaccine, Penmenvy, received approval from the US FDA, offering protection against five common serogroups of Neisseria meningitidis for individuals aged 10 through 25 years. This approval follows positive results from two phase III trials. In China, GSK’s Nucala, a treatment for COPD, is under review by the National Medical Products Administration, based on data from the Phase III MATINEE trial.
On the analyst front, Morgan Stanley (NYSE:MS) initiated coverage on GSK with an underweight rating, citing concerns over the Inflation Reduction Act and vaccine market disruptions. Meanwhile, CFRA revised GSK’s stock price target to $40.00, maintaining a Hold rating due to underperformance in the Vaccines segment. Despite the challenges, GSK’s robust performance in Specialty Medicines and its strategic initiatives continue to shape its market presence.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.